Virginia Merino

Valencia, VC 46022, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Model-Based Design of Sustained-Release Formulations of Anti-TNF-α Monoclonal Antibodies for Intravitreal Administration.

Model-Based Design of Sustained-Release Formulations of Anti-TNF-α Monoclonal Antibodies for Intravitreal Administration.

Journal: Pharmaceutics

Published: February 20, 2026

Impact of shelf-life on the pharmaceutical equivalence assessment of a hydrocortisone semisolid W/O emulsion: Evaluation of rheological, structural, and release properties.

Impact of shelf-life on the pharmaceutical equivalence assessment of a hydrocortisone semisolid W/O emulsion: Evaluation of rheological, structural, and release properties.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: February 05, 2026

Dosing interval optimization and persistence with faricimab in age-related macular degeneration: An observational study in real-world clinical practice.

Dosing interval optimization and persistence with faricimab in age-related macular degeneration: An observational study in real-world clinical practice.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: August 31, 2025

Dosing interval optimization and persistence with faricimab in age-related macular degeneration: An observational study in real-world clinical practice.

Dosing interval optimization and persistence with faricimab in age-related macular degeneration: An observational study in real-world clinical practice.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: August 31, 2025

Dosing interval optimization and persistence with faricimab in age-related macular degeneration: An observational study in real-world clinical practice.

Dosing interval optimization and persistence with faricimab in age-related macular degeneration: An observational study in real-world clinical practice.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: August 31, 2025

A physiologically based pharmacokinetic model to describe [89Zr]Zr-DFO-Adalimumab specific activity after intravitreal administration to rats with endotoxin-induced uveitis.

A physiologically based pharmacokinetic model to describe [89Zr]Zr-DFO-Adalimumab specific activity after intravitreal administration to rats with endotoxin-induced uveitis.

Journal: International journal of pharmaceutics

Published: April 16, 2025

Innovative Famciclovir Eye Drop Formulations for Herpes Zoster Infections.

Innovative Famciclovir Eye Drop Formulations for Herpes Zoster Infections.

Journal: Current eye research

Published: March 02, 2025

An Antibacterial-Loaded PLA 3D-Printed Model for Temporary Prosthesis in Arthroplasty Infections: Evaluation of the Impact of Layer Thickness on the Mechanical Strength of a Construct and Drug Release.

An Antibacterial-Loaded PLA 3D-Printed Model for Temporary Prosthesis in Arthroplasty Infections: Evaluation of the Impact of Layer Thickness on the Mechanical Strength of a Construct and Drug Release.

Journal: Pharmaceutics

Published: June 27, 2024

Impact of Time on Parameters for Assessing the Microstructure Equivalence of Topical Products: Diclofenac 1% Emulsion as a Case Study.

Impact of Time on Parameters for Assessing the Microstructure Equivalence of Topical Products: Diclofenac 1% Emulsion as a Case Study.

Journal: Pharmaceutics

Published: April 02, 2024

Pharmaceutical Compounding in Veterinary Medicine: Suspension of Itraconazole.

Pharmaceutical Compounding in Veterinary Medicine: Suspension of Itraconazole.

Journal: Pharmaceutics

Published: March 08, 2024

In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug.

In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug.

Journal: Pharmaceutics

Published: January 31, 2024

Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union.

Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union.

Journal: Pharmaceutics

Published: January 10, 2023

Showing 1-12 of 58

Last Updated: 09/26/2026